Antibody-containing formulation

In a non-limiting embodiment, the present disclosure pertains to an antibody-containing formulation containing an anti-IL-6 receptor antibody as an active ingredient, the formulation containing a histidine-aspartate buffer or a histidine-glutamate buffer, Poloxamer 188, and arginine and having a pH...

Full description

Saved in:
Bibliographic Details
Main Authors KAMEOKA, DAISUKE, IMAI, CHIFUMI, FUKUDA, MASAKAZU, IGAWA, TOMOYUKI, WATANABE, ATSUSHI, HAYASAKA, AKIRA, YASUTAKE, MASAYA
Format Patent
LanguageChinese
English
Published 16.03.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:In a non-limiting embodiment, the present disclosure pertains to an antibody-containing formulation containing an anti-IL-6 receptor antibody as an active ingredient, the formulation containing a histidine-aspartate buffer or a histidine-glutamate buffer, Poloxamer 188, and arginine and having a pH of 5.5-6.6. In a non-limiting embodiment, the present disclosure pertains to a method for stabilizing an antibody-containing solution, a method for suppressing the association (for example, dimerization) of antibodies, and a method for suppressing the production of insoluble particles, the methods being characterized by involving: adding L-aspartic acid or L-glutamic acid; and optionally adding Poloxamer 188.
Bibliography:Application Number: TW202110119429